Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.

Okabe, Seiichi; Tauchi, Tetsuzo; Tanaka, Yuko; Ohyashiki, Kazuma

Okabe, Seiichi; Tauchi, Tetsuzo; Tanaka, Yuko; Ohyashiki, Kazuma.

Affiliation

Okabe S; First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan. okabe@tokyo-med.ac.jp

Biochem Biophys Res Commun ; 435(3): 506-11, 2013 Jun 07.

Article in En | MEDLINE | ID: mdl-23684619

Subject(s)

Fusion Proteins, bcr-abl/antagonists & inhibitors; Imidazoles/pharmacology; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/enzymology; Protein Kinase Inhibitors/pharmacology; Protein-Tyrosine Kinases/antagonists & inhibitors; Pyridazines/pharmacology; Antineoplastic Agents/pharmacology; Cell Line, Tumor; Drug Resistance, Neoplasm/genetics; Fusion Proteins, bcr-abl/genetics; Fusion Proteins, bcr-abl/metabolism; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics; Protein-Tyrosine Kinases/genetics; Protein-Tyrosine Kinases/metabolism

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyridazines / Protein-Tyrosine Kinases / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Fusion Proteins, bcr-abl / Protein Kinase Inhibitors / Imidazoles Limits: Humans Language: En Journal: Biochem Biophys Res Commun Year: 2013 Type: Article Affiliation country: Japan

Fulltext

XML

PubMed Links

Search on Google